Advertisement
Advertisement
U.S. markets open in 8 hours 17 minutes
Advertisement
Advertisement
Advertisement
Advertisement

ShockWave Medical, Inc. (SWAV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
189.47+12.07 (+6.80%)
At close: 04:00PM EST
191.19 +1.72 (+0.91%)
After hours: 06:36PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close177.40
Open180.80
Bid0.00 x 800
Ask0.00 x 1000
Day's Range180.80 - 192.00
52 Week Range91.46 - 249.73
Volume358,097
Avg. Volume282,511
Market Cap6.689B
Beta (5Y Monthly)1.30
PE Ratio (TTM)N/A
EPS (TTM)-1.09
Earnings DateFeb 15, 2022 - Feb 21, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est246.80
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for SWAV

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ShockWave Medical, Inc.
    Analyst Report: Guardant Health, Inc.Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company’s pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.
    Rating
    Fair Value
    Economic Moat
    11 hours agoMorningstar
View more
  • Simply Wall St.

    What Is ShockWave Medical, Inc.'s (NASDAQ:SWAV) Share Price Doing?

    While ShockWave Medical, Inc. ( NASDAQ:SWAV ) might not be the most widely known stock at the moment, it received a lot...

  • GlobeNewswire

    Shockwave Medical Enrolls First Patient in Disrupt BTK II Study for Long, Calcified, Below the Knee Lesions

    Global Post-Market Study Will Assess Long-Term Benefit of Peripheral IVL on the Most Challenging Calcified Lesions, Including Patients with Critical Limb IschemiaSANTA CLARA, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced the start of the Disrupt BTK II post-market study to assess the safety, effectiveness and optimal clinical use

  • GlobeNewswire

    Shockwave Medical to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

    SANTA CLARA, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that the company will be participating in the Piper Sandler 33rd Annual Virtual Healthcare Conference, scheduled to be held from November 29 to December 2, 2021. Shockwave management is scheduled for a live fireside chat on Wednesday, December 1, 2021, at 1:30 p.m. Eastern

Advertisement
Advertisement